A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated myeloid malignancies

Lachowiez, CA; Loghavi, S; Zeng, Z; Tanaka, T; Kim, YJ; Uryu, H; Turkalj, S; Jakobsen, NA; Luskin, MR; Duose, DY; Tidwell, RSS; Short, NJ; Borthakur, G; Kadia, TM; Masarova, L; Tippett, GD; Bose, P; Jabbour, EJ; Ravandi, F; Daver, NG; Garcia-Manero, G; Kantarjian, H; Garcia, JS; Vyas, P; Takahashi, K; Konopleva, M; DiNardo, CD

Journal article

A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated myeloid malignancies

Abstract:: The safety and efficacy of combining the isocitrate dehydrogenase-1 (IDH1) inhibitor ivosidenib (IVO) with the BCL2 inhibitor venetoclax (VEN; IVO + VEN) ± azacitidine (AZA; IVO + VEN + AZA) were evaluated in four cohorts of patients with IDH1-mutated myeloid malignancies (n = 31). Most (91%) adverse events were grade 1 or 2. The maximal tolerated dose was not reached. Composite complete remission with IVO + VEN + AZA versus IVO + VEN was 90% versus 83%. Among measurable residual disease (MRD)–evaluable patients (N = 16), 63% attained MRD-negative remissions; IDH1 mutation clearance occurred in 64% of patients receiving ≥5 treatment cycles (N = 14). Median event-free survival and overall survival were 36 [94% CI, 23–not reached (NR)] and 42 (95% CI, 42-NR) months. Patients with signaling gene mutations appeared to particularly benefit from the triplet regimen. Longitudinal single-cell proteogenomic analyses linked cooccurring mutations, antiapoptotic protein expression, and cell maturation to therapeutic sensitivity of IDH1-mutated clones. No IDH isoform switching or second-site IDH1 mutations were observed, indicating combination therapy may overcome established resistance pathways to single-agent IVO.
Significance: IVO + VEN + AZA is safe and active in patients with IDH1-mutated myeloid malignancies. Combination therapy appears to overcome resistance mechanisms observed with single-agent IDH-inhibitor use, with high MRD-negative remission rates. Single-cell DNA ± protein and time-of-flight mass-cytometry analysis revealed complex resistance mechanisms at relapse, highlighting key pathways for future therapeutic intervention.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Lachowiez, C. A., Loghavi, S., Zeng, Z., Tanaka, T., Kim, Y. J., Uryu, H., Turkalj, S., Jakobsen, N. A., Luskin, M. R., Duose, D. Y., Tidwell, R. S. S., Short, N. J., Borthakur, G., Kadia, T. M., Masarova, L., Tippett, G. D., Bose, P., Jabbour, E. J., Ravandi, F., … DiNardo, C. D. (2023). A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discovery, 4(4), 276–293.

MLA Style

Lachowiez, CA, et al. “A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.” Blood Cancer Discovery, vol. 4, no. 4, 2023, pp. 276–93.

Chicago Style

Lachowiez, CA, S Loghavi, Z Zeng, et al. 2023. “A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.” Blood Cancer Discovery 4 (4): 276–93.
Print